Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04060862 |
Title | A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150) |
Acronym | IPATunity150 |
Recruitment | Terminated |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | Hoffmann-La Roche |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | GBR | ESP | CAN | BRA | AUS |